Clinical trial
An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in…
NCT00274443 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00274443 |
|---|---|
| Title | An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin |
| Official title | An Open -Label, Phase II Trial of Increasing Doses of ABI-007 and Carboplatin in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | Celgene, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer (NSCLC) |
| Intervention type | Drug |
| Interventions | ABI-007 (Abraxane) and Carboplatin |
| Enrollment | 250 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Jan 11, 2006 |
| Last update posted | Nov 12, 2019 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: